8-K
Marchex Inc (MCHX)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2025
Marchex, Inc.
(Exact name of Registrant as Specified in its Charter)
| Delaware | 000-50658 | 35-2194038 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission File Number) | (IRS Employer<br><br>Identification No.) |
| 1200 5th Ave, Suite 1300,<br><br>Seattle, Washington | 98101 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (206) 331-3300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Class B Common Stock, par value $0.01 per share | MCHX | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
The information set forth under Item 5.02 of this Current Report on Form 8-K is incorporated herein by reference.
Item 2.02 Results of Operations and Financial Condition.
On March 6, 2025, Marchex, Inc. (“Marchex” or the "Company") is issuing a press release and holding a conference call regarding its financial results for the fourth quarter and full year ended December 31, 2024 (the “Press Release”). The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Marchex is referencing non-generally accepted accounting principles ("GAAP") financial information in both the Press Release and on the conference call. A reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures is contained in the attached Press Release. Disclosures regarding definitions of these financial measures used by Marchex and why Marchex’s management believes these financial measures provide useful information to investors is also included in the Press Release.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements for Certain Officers.
On March 6, 2025, Marchex announces that Brian Nagle (“Nagle”), SVP, Corporate Controller of Marchex, had been appointed Principal Financial Officer and Principal Accounting Officer of the Company. Nagle, age 39, joined Marchex in August, 2024; previously served as Vice President of Financial Reporting of Seekr Technologies from 2022 to 2024; Director, SEC Reporting and Technical Accounting of Emergent BioSolutions from 2021 to 2022 and previously as Senior Manager of SEC Reporting and Technical Accounting from 2019 to 2021; and held several positions at KPMG, LLP from 2008 to 2019, most recently as Senior Manager, Audit. Mr. Nagle is a Certified Public Accountant.
In connection with his appointment, Marchex has entered into its standard form indemnity agreement for Marchex’s Section 16 executive officers and directors with Nagle. There is no family relationship between Nagle and any other executive officer or director of Marchex and there is no arrangement or understanding between Nagle and any other person pursuant to which he was appointed Principal Financial Officer and Principal Accounting officer of Marchex. There are no transactions in which Nagle has an interest requiring disclosure under Item 404(a) of Regulation S-K and there were no compensation changes in connection with this appointment.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit<br><br>No. | Description |
|---|---|
| 99.1 | Press Release of Marchex, dated March 6, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Marchex has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
| MARCHEX, INC. | ||
|---|---|---|
| Date: March 6, 2025 | By: | /s/ BRIAN NAGLE |
| Name: | Brian Nagle | |
| Title: | Principal Financial Officer |
EX-99.1
Exhibit 99.1
Marchex Announces Fourth Quarter and Full Year 2024 Results
SEATTLE, WA – March 6, 2025 – Marchex, Inc. (NASDAQ: MCHX), which harnesses the power of artificial intelligence ("AI") and conversational intelligence to drive operational excellence and revenue acceleration, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Q4 2024 and Full Year 2024 Financial Highlights
- GAAP revenue was $11.9 million for the fourth quarter of 2024, compared to $12.4 million for the fourth quarter of 2023. GAAP revenue was $48.1 million for 2024, compared to $49.9 million for 2023.
- Net loss was $1.9 million for the fourth quarter of 2024 or $(0.04) per diluted share, compared to a net loss of $1.1 million or $(0.02) per diluted share for the fourth quarter of 2023. Net loss was $4.9 million for 2024 or $(0.11) per diluted share, compared to a net loss of $9.9 million for 2023 or $(0.23) per diluted share.
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In Thousands) | 2024 | 2023 | 2024 | 2023 | |||||||
| GAAP Revenue | $ | 11,923 | $ | 12,395 | $ | 48,122 | $ | 49,910 | |||
| Non-GAAP Results: | |||||||||||
| Adjusted EBITDA(1) | $ | (386 | ) | $ | 112 | $ | (230 | ) | $ | (3,365 | ) |
- Adjusted earnings before interest, taxes, depreciation, and amortization ("EBITDA") for the year ended December 31, 2024 and 2023 include approximately $235 and $1,620 of reorganization costs, respectively. Excluding these amounts would result in an Adjusted EBITDA of $5 and $(1,745), respectively.
- Adjusted non-GAAP loss per share for the fourth quarter of 2024 was $(0.03), compared to $0.00 for the fourth quarter of 2023. Adjusted non-GAAP loss per share for 2024 was $(0.06), compared to $(0.12) for 2023.
Q4 2024 Summary:
- New Products Introduction: The Company announced the phased rollout of its vertical-specific advanced AI solutions for lead identification, lead value assessment, and trending topics discovery. These innovative AI solutions deliver descriptive, predictive, and prescriptive insights that enable businesses to improve return on ad spend, understand the primary elements driving changes in customer behavior, and increase sales. These solutions are tailored for automotive original equipment manufacturers ("OEMs") and dealers, home services, medical, dental, and automotive services.
- New Partnerships: The Company announced a partnership with Microsoft to join Microsoft’s Cloud AI Partner Program which will include the ability to transact through the Microsoft Azure Marketplace. The partnership is currently anticipated to launch later in the second quarter of 2025.
- Conversation Volumes: Due to typical seasonality, overall conversation volumes were lower in the fourth quarter compared to the third quarter of 2024.
Strategic Priorities and Growth Initiatives For 2025:
New Customer Traction and Existing Customer Expansion. The Company currently plans to invest in sales force growth and expansion into new channel partnerships, as well as utilize its product progress to expand relationships within its existing enterprise customer base, and also drive additional customer relationships across multiple verticals. We anticipate this progress should accelerate growth over the course of the year.
New Product Innovation. The Company anticipates ongoing expansion of its suite of award-winning AI solutions, including launching new AI solutions, throughout 2025.
Expand Channel Opportunities. The Company anticipates launching its partnership with Microsoft and adding additional channel partners throughout the course of 2025 to expand its sales reach and customer footprint.
“Marchex is making significant progress in transitioning to a platform-based, growth company,” said Edwin Miller, Chief Executive Officer. “In the fourth quarter of 2024, we completed foundational infrastructure initiatives that enable the Company to transition to customer-focused innovation and other growth initiatives. In 2025, we are highly focused on extending our progress and investing resources to capitalize on our opportunity in creating a leading conversational intelligence company. We anticipate completing critical customer facing applications, launching new innovative AI solutions, expanding our sales reach and forming new partnerships which we believe will be catalysts for meaningful acceleration and can help us take important steps forward in our mission to build a $100 million plus business.”
Business Outlook
The following forward-looking statements reflect Marchex's expectations as of March 6, 2025.
For the first quarter ending March 31, 2025:
- Revenue is currently anticipated to be in the range of fourth quarter 2024 levels.
- Adjusted EBITDA, excluding certain one-time expenses associated with organizational realignment, is currently anticipated to be in the range of fourth quarter 2024 levels. This takes into account typically higher first quarter operating expenses as compared to the fourth quarter of 2024 and some overlap of charges related to the completion of OneStack initiatives.
For the Fiscal Year 2025:
- Revenue is currently anticipated to grow on a year-over-year basis, with the opportunity for sequential revenue acceleration throughout 2025, as we execute on a series of strategic, sequential product launch and go-to-market initiatives.
- Gross margins for the full year 2025 are currently anticipated to be higher than 2024, with the opportunity for improvement during the year.
- Adjusted EBITDA is currently anticipated to be positive for the full year 2025. Given the current belief that the Company can increase revenue sequentially while also continuing to gain expense efficiencies, the Company believes it has the opportunity to see meaningful improvements in sequential quarterly Adjusted EBITDA. To the extent this progress manifests throughout the year, we may have the ability to allocate some of these potential gains into incremental discretionary investments in growth initiatives.
“2024 was a year of transformation and we are highly focused on making 2025 a year of acceleration. With a strong foundation in place and a clear vision, we are confident in our ability to deliver sustainable growth while exercising financial discipline and creating long-term value for our customers and shareholders,” said Miller.
Management will hold a conference call, starting at 5:00 p.m. Eastern Time on Thursday, March 6, 2025, to discuss its fourth quarter and full year 2024 financial results and other Company updates. Access to the live webcast of the conference call will be available online from the Investors section of Marchex’s website at www.marchex.com. An archived version of the webcast will also be available at the same location two hours after completion of the call.
About Marchex
Marchex harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communication channels. Through our prescriptive analytics solutions, we enable the alignment of enterprise strategy, empowering businesses to increase revenue through informed decision-making and strategic execution. Marchex provides conversational intelligence AI-powered solutions for market-leading companies in leading business-to-business-to-consumer vertical markets, including several of the world’s most innovative and successful brands.
Please visit http://www.marchex.com, www.marchex.com/blog or @marchex on X (formally known as Twitter), where Marchex discloses material information from time to time about the Company, its financial information, and its business.
Forward-Looking Statements:
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, other financial guidance, acquisitions, dispositions, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Marchex's actual results to differ materially from those indicated by such forward-looking statements including but not limited to product demand, order cancellations and delays, competition and general economic conditions. These factors are described in greater detail in the "Risk Factors" section of our most recent periodic report and registration statement filed with the Securities and Exchange Commission. All of the information provided in this release is as of March 6, 2025, and Marchex undertakes no duty to update the information provided herein.
In the event the press release contains links to third party websites or materials, the links are provided solely as a convenience to the user. Marchex is not responsible for the content of linked third-party sites or materials and does not make any representations regarding the content or accuracy thereof.
Non-GAAP Financial Information:
To supplement Marchex's consolidated financial statements presented in accordance with GAAP and to provide clarity internally and externally, Marchex uses certain non-GAAP measures of financial performance and liquidity, including Adjusted EBITDA, Adjusted operating income (loss) before depreciation and amortization ("OIBA"), and Adjusted non-GAAP income (loss) per share. Financial analysts and investors may use Adjusted EBITDA and Adjusted OIBA to help with comparative financial evaluation to make informed investment decisions. Financial analysts and investors may use Adjusted non-GAAP income (loss) per share to analyze Marchex's financial performance since these groups have historically used earnings per share related measures, along with other measures, to estimate the value of a company, to make informed investment decisions, and to evaluate a company's operating performance compared to that of other companies in its industry.
Adjusted EBITDA represents net income (loss) before (1) interest, (2) income taxes, (3) amortization of intangible assets from acquisitions, (4) depreciation and amortization, (5) stock-based compensation expense, and (6) acquisition and disposition-related costs. Adjusted EBITDA is an alternative measure used by our management to understand and evaluate our core operating performance and trends, and management believes it
provides meaningful supplemental information regarding the Company's liquidity and ability to fund its operations and financing obligations.
Adjusted OIBA represents Adjusted EBITDA adjusted for depreciation and amortization. This measure, among other things, is another metric by which Marchex has evaluated the performance of its business, to include being the basis on which Marchex's internal budgets have been based and by which Marchex's management has been evaluated. This measure represents Marchex's consolidated operating results, taking into account depreciation and other intangible amortization, but excluding the effects of certain other expenses removed in arriving at Adjusted EBITDA, as detailed above.
Adjusted non-GAAP income (loss) per share represents Adjusted non-GAAP income (loss) divided by GAAP diluted shares outstanding. Adjusted non-GAAP income (loss) generally captures those items on the statement of operations that have been, or ultimately will be, settled in cash exclusive of certain items that are not indicative of Marchex’s recurring core operating results and represents net income (loss) applicable to common stockholders plus the net of tax effects of: (1) stock-based compensation expense, (2) acquisition and disposition related costs, (3) amortization of intangible assets from acquisitions, and (4) interest (income) expense and other, net.
Marchex's management believes that investors should have access to, and Marchex is obligated to provide, the same set of tools that management uses in analyzing the Company's results. These non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, and should not be considered in isolation, as a substitute for, or superior to, GAAP results. Marchex’s non-GAAP financial measures may be defined differently from time to time and may be defined differently than similar titled terms used by other companies, and accordingly, care should be exercised in understanding how Marchex defines its non-GAAP financial measures in this release. Marchex endeavors to compensate for the limitations of the non-GAAP measures presented by providing the comparable GAAP measure with equal or greater prominence, GAAP financial statements, and detailed descriptions of the reconciling items and adjustments, including quantifying such items, to derive the non-GAAP measure.
For further information, contact:
Trevor Caldwell Marchex Investor Relations
Telephone: 206.331.3600 Email: ir@marchex.com
Or
MEDIA INQUIRIES
Marchex Corporate Communications
Telephone: 206.331.3434
Email: pr@marchex.com
MARCHEX, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue | $ | 11,923 | $ | 12,395 | $ | 48,122 | $ | 49,910 | ||||
| Expenses: | ||||||||||||
| Cost of revenue (1) | 4,381 | 4,683 | 17,172 | 20,582 | ||||||||
| Sales and marketing (1) | 3,382 | 2,492 | 12,136 | 11,412 | ||||||||
| Product development (1) | 2,841 | 3,154 | 12,414 | 15,355 | ||||||||
| General and administrative (1) | 2,754 | 2,792 | 10,245 | 10,205 | ||||||||
| Amortization of intangible assets from acquisitions | 151 | 394 | 602 | 1,987 | ||||||||
| Acquisition and disposition related costs | — | — | — | 12 | ||||||||
| Total operating expenses | 13,509 | 13,515 | 52,569 | 59,553 | ||||||||
| Loss from operations | (1,586 | ) | (1,120 | ) | (4,447 | ) | (9,643 | ) | ||||
| Interest income (expense) and other, net | (30 | ) | 19 | (120 | ) | (173 | ) | |||||
| Loss before income tax expense | (1,616 | ) | (1,101 | ) | (4,567 | ) | (9,816 | ) | ||||
| Income tax expense | 294 | 42 | 380 | 94 | ||||||||
| Net loss applicable to common stockholders | $ | (1,910 | ) | $ | (1,143 | ) | $ | (4,947 | ) | $ | (9,910 | ) |
| Basic and diluted net loss per Class A and Class B share applicable to common stockholders | $ | (0.04 | ) | $ | (0.02 | ) | $ | (0.11 | ) | $ | (0.23 | ) |
| Shares used to calculate basic net loss per share applicable to common stockholders: | ||||||||||||
| Class A | 4,661 | 4,661 | 4,661 | 4,661 | ||||||||
| Class B | 38,539 | 38,059 | 38,498 | 37,960 | ||||||||
| Shares used to calculate diluted net loss per share applicable to common stockholders: | ||||||||||||
| Class A | 4,661 | 4,661 | 4,661 | 4,661 | ||||||||
| Class B | 43,200 | 42,720 | 43,159 | 42,621 | ||||||||
| (1) Includes stock-based compensation allocated as follows: | ||||||||||||
| Cost of revenue | $ | 9 | $ | 3 | $ | 24 | $ | 2 | ||||
| Sales and marketing | 90 | 83 | 308 | 663 | ||||||||
| Product development | 19 | 20 | 54 | 114 | ||||||||
| General and administrative | 307 | 380 | 1,321 | 1,614 | ||||||||
| Total | $ | 425 | $ | 486 | $ | 1,707 | $ | 2,393 |
MARCHEX, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands)
(unaudited)
| December 31, | ||||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 12,767 | $ | 14,607 | ||
| Accounts receivable, net | 7,072 | 7,394 | ||||
| Prepaid expenses and other current assets | 2,439 | 1,805 | ||||
| Total current assets | 22,278 | 23,806 | ||||
| Property and equipment, net | 1,811 | 2,398 | ||||
| Other assets, net | 397 | 1,482 | ||||
| Right-of-use lease assets | 1,156 | 1,631 | ||||
| Goodwill | 17,558 | 17,558 | ||||
| Intangible assets from acquisitions, net | — | 602 | ||||
| Total assets | $ | 43,200 | $ | 47,477 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 1,349 | $ | 1,533 | ||
| Accrued benefits and payroll | 2,133 | 3,294 | ||||
| Other accrued expenses and current liabilities | 4,197 | 3,217 | ||||
| Deferred revenue and deposits | 1,093 | 1,214 | ||||
| Operating lease liability, current | 495 | 462 | ||||
| Total current liabilities | 9,267 | 9,720 | ||||
| Deferred tax liabilities | 579 | 249 | ||||
| Finance lease liability, non-current | — | 421 | ||||
| Operating lease liability, non-current | 721 | 1,217 | ||||
| Total liabilities | 10,567 | 11,607 | ||||
| Stockholders’ equity: | ||||||
| Class A common stock | 49 | 49 | ||||
| Class B common stock | 390 | 386 | ||||
| Additional paid-in capital | 358,372 | 356,666 | ||||
| Accumulated deficit | (326,178 | ) | (321,231 | ) | ||
| Total stockholders’ equity | 32,633 | 35,870 | ||||
| Total liabilities and stockholders’ equity | $ | 43,200 | $ | 47,477 |
MARCHEX, INC. AND SUBSIDIARIES
(in thousands)
(unaudited)
Reconciliation of Net Loss to Adjusted EBITDA and Adjusted OIBA
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net loss applicable to common stockholders | $ | (1,910 | ) | $ | (1,143 | ) | $ | (4,947 | ) | $ | (9,910 | ) |
| Interest (income) expense and other, net | 30 | (19 | ) | 120 | 173 | |||||||
| Income tax expense | 294 | 42 | 380 | 94 | ||||||||
| Amortization of intangible assets from acquisitions | 151 | 394 | 602 | 1,987 | ||||||||
| Depreciation and amortization | 624 | 352 | 1,908 | 1,886 | ||||||||
| Stock-based compensation | 425 | 486 | 1,707 | 2,393 | ||||||||
| Acquisition and disposition-related costs | — | — | — | 12 | ||||||||
| Adjusted EBITDA | $ | (386 | ) | $ | 112 | $ | (230 | ) | $ | (3,365 | ) | |
| Depreciation and amortization | 624 | 352 | 1,908 | 1,886 | ||||||||
| Adjusted OIBA | $ | (1,010 | ) | $ | (240 | ) | $ | (2,138 | ) | $ | (5,251 | ) |
MARCHEX, INC. AND SUBSIDIARIES
(in thousands)
(unaudited)
Reconciliation of Net Loss per Share to Adjusted Non-GAAP Loss(1)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net loss applicable to common stockholders, diluted | $ | (0.04 | ) | $ | (0.02 | ) | $ | (0.11 | ) | $ | (0.23 | ) |
| Stock-based compensation | 0.01 | 0.01 | 0.04 | 0.06 | ||||||||
| Acquisition and disposition-related costs | - | - | - | - | ||||||||
| Amortization of intangible assets from acquisitions | - | 0.01 | 0.01 | 0.05 | ||||||||
| Interest (income) expense and other, net | - | - | - | - | ||||||||
| Adjusted non-GAAP loss per share | $ | (0.03 | ) | $ | - | $ | (0.06 | ) | $ | (0.12 | ) | |
| Shares used to calculate diluted net loss per share applicable to common stockholders (GAAP) and Adjusted non-GAAP loss per share | 43,200 | 42,720 | 43,159 | 42,621 |
- For the purpose of computing the number of diluted shares for Adjusted non-GAAP income (loss) per share, Marchex uses the accounting guidance that would be applicable for computing the number of diluted shares for GAAP net income (loss) per share.